Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRAF3-interacting JNK-activating modulator (TRAF3IP3, also known as T3JAM) is an intracellular adapter protein encoded by the TRAF3IP3 gene. TRAF3IP3 regulates both innate and adaptive immunity and is essential for T and B cell development, as well as for regulatory T cell stability and function[2][8][1]. Mechanistically, it modulates signal transduction mediated by the c-Jun N-terminal kinase (JNK) pathway, interacts with TRAF3 and TBK1, and regulates the type I interferon response to cytosolic viral RNA by facilitating the degradative ubiquitination of TBK1[1][2]. It also acts in macrophages to positively regulate TLR4 signaling, contributing to inflammation, and suppresses excessive innate immune activation to maintain immune homeostasis[10][8]. TRAF3IP3 interacts with several partners, including STRN, MOBKL3, STK24, and FAM40A, and plays a role in numerous intracellular signaling pathways relevant to immune cell function and growth[3]. There are no known approved drugs that directly target TRAF3IP3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TRAF3-interacting JNK-activating modulator (TRAF3IP3).